<DOC>
	<DOCNO>NCT00007852</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody rituximab locate cancer cell either kill deliver cancer-killing substance without harm normal cell . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation bone marrow transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . PURPOSE : Phase II trial study effectiveness rituximab combination chemotherapy follow bone marrow peripheral stem cell transplantation treat patient relapsed refractory non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Rituximab Combination Chemotherapy Followed Bone Marrow Peripheral Stem Cell Transplantation Treating Patients With Relapsed Refractory Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine complete partial response rate patient relapse refractory B-cell non-Hodgkin 's lymphoma treat rituximab high-dose carmustine , etoposide , cytarabine melphalan follow autologous bone marrow peripheral blood stem cell transplantation . II . Determine toxicity profile regimen patient . III . Compare level soluble CD20 antigen rituximab blood level patient outcomes patient population . OUTLINE : Patients receive two dos rituximab IV 3-4 hour 1 week apart . Stem cell peripheral blood bone marrow collect least 1 week second dose rituximab . Following stem cell collection , patient receive third dose rituximab IV day -10 -6 . Patients receive high-dose chemotherapy consist carmustine IV day -6 , etoposide IV twice daily cytarabine IV day -5 -2 , melphalan IV day -1 . On day 0 patient undergo autologous bone marrow peripheral blood stem cell transplantation . After transplantation , patient receive fourth dose rituximab approximately day 30 , weekly 4 week approximately 6 month absence disease progression unacceptable toxicity . Patients follow 1 year annually thereafter . PROJECTED ACCRUAL : A total 23-40 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis CD20positive Bcell nonHodgkin 's lymphoma Transplantation candidate Primary induction failure Chemotherapy refractory disease Received least 3 prior chemotherapy regimen OR Diagnosis mantle cell lymphoma No history Tcell lymphoma No relapse progression rituximab therapy within 3 month transplantation PATIENT CHARACTERISTICS : Age : 19 Performance status : WHO 02 Life expectancy : At least 6 month Hematopoietic : Absolute neutrophil count least 1,000/mm3* Platelet count 50,000/mm3* Hemoglobin 9.0 g/dL* *Unless due lymphomatous involvement marrow Hepatic : Not specify Renal : Not specify Other : No serious disease condition would preclude study Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics Chemotherapy : See Disease Characteristics No concurrent chemotherapy Endocrine therapy : No concurrent corticosteroid except transient control prevention nausea vomit Concurrent nonsteroidal hormone nonlymphomarelated condition ( e.g. , insulin diabetes ) allow Radiotherapy : No concurrent external beam radiotherapy transplantation therapy Surgery : Not specify Other : No concurrent antitumoral investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>